Brief: HBM Holdings Says Unit & Sichuan Kelun-Biotech Biopharmaceutical Entered License Agreement
09/12/2022 01:16
Dec 9 (Reuters) - Hbm Holdings Ltd 2142.HK :
* UNIT & SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL HAVE
ENTERED INTO
A LICENSE AGREEMENT
* AGREEMENT TO LICENSE KELUN-BIOTECH TO USE UNIT'S
PROPRIETARY
FULLY H2L2 TRANSGENIC HARBOUR MICE ® PLATFORM
Source text for Eikon: ID:nHKSrXJlN
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study